blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2992013

EP2992013 - ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.10.2020
Database last updated on 20.09.2024
FormerThe patent has been granted
Status updated on  01.11.2019
FormerGrant of patent is intended
Status updated on  21.07.2019
FormerExamination is in progress
Status updated on  03.02.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Teva Pharmaceuticals Australia Pty Ltd
Level 2
37 Epping Road
Macquarie Park, NSW 2113 / AU
[2016/10]
Inventor(s)01 / CLARKE, Adam
37 Epping Road
Level 2
Macquarie Park, NSW 2113 / AU
02 / POLLARD, Matthew
37 Epping Road
Level 2
Macquarie Park, NSW 2113 / AU
03 / DOYLE, Anthony, Gerard
37 Epping Road
Level 2
Macquarie Park, NSW 2113 / AT
04 / BEHRENS, Collette
37 Epping Road
Level 2
Macquarie Park, NSW 2113 / AU
05 / YAMAGISHI, Tetsuo
37 Epping Road
Level 2
Macquarie Park, NSW 2113 / AU
06 / WILSON, David, S. Jr.
610 Galveston Drive
Redwood City, CA 94063 / US
07 / POGUE, Sarah, L.
5471 Midday Common
Freemont, CA 94555 / US
08 / TAURA, Tetsuya
514 Driscoll Place
Palo Alto, CA 94306 / US
 [2016/10]
Representative(s)Lee, Nicholas John, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2019/49]
Former [2016/10]Lee, Nicholas John, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date13721243.729.04.2013
[2016/10]
WO2013US38659
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014178820
Date:06.11.2014
Language:EN
[2014/45]
Type: A1 Application with search report 
No.:EP2992013
Date:09.03.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 06.11.2014 takes the place of the publication of the European patent application.
[2016/10]
Type: B1 Patent specification 
No.:EP2992013
Date:04.12.2019
Language:EN
[2019/49]
Search report(s)International search report - published on:EP06.11.2014
ClassificationIPC:C07K16/28, C07K14/00
[2016/10]
CPC:
C07K16/2896 (EP,IL,US); A61K38/212 (EP,US); A61K39/39558 (US);
A61P35/00 (EP); A61P35/02 (EP); C07K14/00 (IL);
C07K14/56 (EP,US); A61K2039/505 (US); A61K38/00 (EP,US);
C07K2317/21 (EP,US); C07K2317/24 (EP,US); C07K2317/41 (EP);
C07K2317/52 (US); C07K2317/56 (EP,US); C07K2317/92 (EP,US);
C07K2319/00 (EP); C07K2319/74 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/10]
Extension statesBA13.11.2015
ME13.11.2015
TitleGerman:ANTI-CD38-ANTIKÖRPER UND FUSIONEN DAVON MIT ABGESCHWÄCHTEM INTERFERON-ALPHA-2B[2016/10]
English:ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B[2016/10]
French:ANTICORPS ANTI-CD38 ET FUSIONS SUR UN INTERFÉRON ALPHA-2B ATTÉNUÉ[2016/10]
Entry into regional phase23.10.2015National basic fee paid 
23.10.2015Designation fee(s) paid 
23.10.2015Examination fee paid 
Examination procedure23.10.2015Amendment by applicant (claims and/or description)
23.10.2015Examination requested  [2016/10]
03.02.2017Despatch of a communication from the examining division (Time limit: M06)
20.07.2017Reply to a communication from the examining division
31.10.2017Despatch of a communication from the examining division (Time limit: M04)
06.02.2018Reply to a communication from the examining division
18.04.2018Despatch of a communication from the examining division (Time limit: M04)
20.08.2018Reply to a communication from the examining division
20.12.2018Despatch of a communication from the examining division (Time limit: M02)
18.02.2019Reply to a communication from the examining division
22.07.2019Communication of intention to grant the patent
29.10.2019Fee for grant paid
29.10.2019Fee for publishing/printing paid
29.10.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19213030.0  / EP3677591
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.02.2017
Opposition(s)07.09.2020No opposition filed within time limit [2020/46]
Fees paidRenewal fee
23.10.2015Renewal fee patent year 03
21.04.2016Renewal fee patent year 04
21.04.2017Renewal fee patent year 05
23.04.2018Renewal fee patent year 06
23.04.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.04.2013
AL04.12.2019
CY04.12.2019
CZ04.12.2019
DK04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
MC04.12.2019
MK04.12.2019
MT04.12.2019
RO04.12.2019
RS04.12.2019
SI04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
LU29.04.2020
[2022/32]
Former [2022/27]HU29.04.2013
AL04.12.2019
CY04.12.2019
CZ04.12.2019
DK04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
MC04.12.2019
MT04.12.2019
RO04.12.2019
RS04.12.2019
SI04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
LU29.04.2020
Former [2021/08]AL04.12.2019
CZ04.12.2019
DK04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
MC04.12.2019
RO04.12.2019
RS04.12.2019
SI04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
LU29.04.2020
Former [2020/52]AL04.12.2019
CZ04.12.2019
DK04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
MC04.12.2019
RO04.12.2019
RS04.12.2019
SI04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
Former [2020/51]AL04.12.2019
CZ04.12.2019
DK04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RO04.12.2019
RS04.12.2019
SI04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
Former [2020/47]AL04.12.2019
CZ04.12.2019
DK04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RO04.12.2019
RS04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
Former [2020/40]AL04.12.2019
CZ04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RO04.12.2019
RS04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
IS04.04.2020
Former [2020/37]AL04.12.2019
CZ04.12.2019
EE04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RO04.12.2019
RS04.12.2019
SK04.12.2019
SM04.12.2019
BG04.03.2020
GR05.03.2020
Former [2020/35]AL04.12.2019
CZ04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RO04.12.2019
RS04.12.2019
BG04.03.2020
GR05.03.2020
Former [2020/32]AL04.12.2019
FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RS04.12.2019
BG04.03.2020
GR05.03.2020
Former [2020/26]FI04.12.2019
HR04.12.2019
LT04.12.2019
LV04.12.2019
RS04.12.2019
BG04.03.2020
GR05.03.2020
Former [2020/23]FI04.12.2019
LT04.12.2019
LV04.12.2019
BG04.03.2020
GR05.03.2020
Former [2020/22]FI04.12.2019
LT04.12.2019
BG04.03.2020
Cited inInternational search[ID]WO0197844  (IDEC PHARMA CORP [US]);
 [I]US2002164788  (ELLIS JONATHAN HENRY [GB], et al);
 [I]WO2005103083  (MORPHOSYS AG [DE], et al);
 [I]WO2007042309  (MORPHOSYS AG [DE], et al);
 [I]WO2011154453  (GENMAB AS [DK], et al);
 [I]WO2012092612  (TAKEDA PHARMACEUTICAL [JP], et al);
 [E]WO2013059885  (CEPHALON AUSTRALIA PTY LTD [AU], et al)
by applicantWO0042072
 WO0197844
 US2003039649
 US6602684
 US7083784
 US7217797
 WO2008006554
 US7326681
 US7388081
 US2009068175
 US2009092599
 US2009142340
 US7732578
 WO2012AU01323
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.